First Solar module volume sold in Q1 2027

First Solar's Q1 2027 guidance hinges on Q4 2026 operational updates. The Q4 2026 earnings report, anticipated around February 23, 2027, will provide updates on actual Q4 2026 module sales performance and future manufacturing capacity, critically influencing Q1 2027 module sales volume guidance ^{[1][4][5][6][7][8][9][10]}. Key factors for this guidance include the status of Series 7 CuRe conversions in India and the U.S., along with the operational decision for the Malaysia facility ^{[1][4][5][6][7][8][9][10]}. Specifically, the India facility expects its first Series 7 CuRe conversion in Q1 2027, impacting the 2027 India finished goods production forecast of 2.2-2.6 GW ^[1][6][7]. In the U.S., the commercial launch of South Carolina Phase 2 is delayed to mid-2027 to incorporate CuRe technology, directly affecting Q1 2027 U.S. finishing capacity, with 2027 South Carolina production projected at 2.2-2.5 GW ^[1][6][8]. A binary decision for the Malaysia facility in H1 2027, whether to operate at its full 1.8 GW annual capacity or shut down, will heavily influence international module volume for Q1 2027 sales ^[1][6][9]. The company expects to maintain its 2027 production guidance at 19-20.5 GW ^[1][2], with CuRe technology projected to generate up to $600 million in potential additional revenue from backlog, primarily in 2027-2028 ^[1][2].

Sales performance, contract resolution, and policy factors will shape guidance. The Q4 2026 earnings report will also reveal actual Q4 2026 module sales against a forecast of 4.3-5.3 GW ^[4][5][10]. Furthermore, the resolution of approximately 4 GW of variable volume from existing contracts, with about half subject to a decision within five months from the Q3 2026 call, will inform Q1 2027 sales potential ^[1][6]. The guidance assumes a consistent U.S. policy environment, including Section 122 tariffs at 15% for 150 days and the Inflation Reduction Act (IRA) as amended ^{[4][11][12][13][8]}. Overall manufacturing capacity is projected to increase from 19 GW in 2026 to 22.1 GW in 2027, with U.S. capacity reaching 17.1 GW and international capacity 1.8 GW in 2027 ^[3].

Analyst forecasts imply a significant range for Q1 2027 module volume. Based on analyst consensus revenue forecasts for Q1 2027 and First Solar's historical average selling price (ASP), the implied range for module volume sold is approximately 3,548 MW to 5,889 MW, with a midpoint calculation yielding approximately 4,483 MW ^[1][2][3][4]. The analyst consensus revenue for First Solar's Q1 2027 (March 2027 quarter) is an average of $1.28B-$1.30B, with a full range of $1.10B-$1.59B ^[1][2][5][6]. The low implied volume of approximately 3,548 MW is calculated using the low revenue estimate of $1.10B and a high ASP of $0.31/W, while the high implied volume of approximately 5,889 MW is derived from the high revenue estimate of $1.59B and a low ASP of $0.27/W ^[1][2][3][4].

Various ASP figures and production forecasts provide further market context. First Solar's 2026 full-year guidance implies an ASP of approximately $0.27-$0.31/W ^[7][8][4], and its Q4 2025 earnings call stated a forecast global ASP of approximately $0.287/W for 2026 volume sold, with U.S. ASP of approximately $0.308/W ^[4][9][10]. While Q1 2027 guidance has not yet been issued as of November 3, 2026, the company's FY2027 production forecast of 18.9–20.5 GW suggests Q1 2027 volume will likely be in the 3.5–4.5 GW range based on seasonal patterns ^{[11][12][13][3][4]}. For historical comparison, First Solar sold 3.8 GW of modules in Q1 2026, which implied an ASP of approximately $0.275/W ^{[3][14][15][16]}. Additionally, the prediction market for 'First Solar module volume sold in Q3 2026' showed a median of 4,197 MW, with the middle half between 4,041–4,363 MW ^[17][18].

First Solar's U.S. operations show strong demand visibility and robust contracted volumes. The company's U.S. production is substantially committed through 2028, supported by a significant backlog of approximately 44 GW as of Q3 2026 ^[1][2][3]. Demand risks in this market primarily stem from policy and project-economics factors, such as Section 232 tariffs and rising battery prices, rather than a deficiency in contracted demand ^[1][2][5]. This robust U.S. position, underpinned by extensive contracted capacity, provides a stable foundation for future deliveries ^[1][2][4].

In contrast, India presents a significantly higher risk to First Solar's Q1 2027 volume targets ^[1][2][4]. The company anticipates finished-goods production of 2.2–2.6 GW in India for 2027; however, this represents a production outlook rather than a guaranteed sales volume, as the facility addresses short-cycle, price-sensitive local demand ^[1][2]. Evidence of this risk appeared in the Q3 2026 update, which reduced 2026 module-volume guidance partly due to a decrease of approximately 0.7 GW in India's domestic forecast alone ^[1][2][4]. The planned Series 7 CuRe conversion, scheduled to commence in Q1 2027 and intended for trial in India as a lower-earnings-impact test site before U.S. implementation, further amplifies the risk for that quarter ^[1][2]. India's market dynamics, encompassing short-cycle demand, demonstrated forecast reductions, price sensitivity, seasonality, and conversion downtime, collectively elevate its risk profile compared to the U.S. market ^[1][2][4].

First Solar's Q1 2027 deliveries estimated 7.7% to 9.1% of backlog. First Solar's contracted backlog of 44.0 GW as of September 30, 2026, is estimated to have a portion of 7.7%–9.1% scheduled for delivery in Q1 2027, based on historical conversion rates ^[1][3][4]. This 44.0 GW figure represents the company's total contracted module sales at that date ^[1][2]. The estimated delivery range for Q1 2027 is derived by applying a quarterly module sales cadence of 3.4–4.0 GW to the total backlog ^[1][3][4]. This cadence reflects First Solar's anticipated first-quarter module sales as reported in its prior full-year 2026 outlook ^[3][4].

Actual Q1 2026 sales provide further specific percentage calculations. Further analysis, using the actual Q1 2026 module sales volume of 3.8 GW, indicates that applying this figure to the 44.0 GW backlog would represent 8.6% of the total ^[1][3][4]. Similarly, using the midpoint of the Q1 2026 outlook range, which was 3.7 GW, yields a portion of 8.4% ^[1][3][4]. For prediction market purposes, a practical point estimate for the module volume sold in Q1 2027 is approximately 3.7 GW, with a reasonable base range of 3.4–4.0 GW ^[5][1][3]. It is important to note that these figures represent an estimate of volume sold, not a disclosed contractual delivery schedule ^[5][1][3].

First Solar's India Series 7 CuRe conversion faces critical Q1 2027 execution risks. The Series 7 CuRe technology conversion at First Solar's India facility, slated to commence in Q1 2027, faces several key execution risks, including potential production downtime during the technology changeover, uncertainties related to trade policy, and the critical need to validate the CuRe deployment process ^{[1][2][3][4][5][6]}. Such risks could lead to production disruption during the first quarter of 2027, potentially impacting India's overall finished goods production for that year ^[1][7][3]. This potential disruption is reflected in the lower end of India's projected 2027 finished goods production, which spans from 2.2 GW to 2.6 GW ^[1][7][3].

Production downtime and trade policy present significant operational and strategic challenges. The technology changeover from Series 7 to CuRe carries a significant risk of production downtime ^{[1][2][3][4][5][6]}. Additionally, trade policy uncertainties, such as Section 232 and Section 301 tariffs, pose a risk to the strategy of leveraging India's front-end output to support U.S. facilities during subsequent Series 7 conversions ^{[1][2][3][4][5][6]}. This support is crucial for maintaining U.S. back-end throughput and preserving partial domestic content and Section 45X eligibility ^{[1][2][3][4][5][6]}.

Validating the CuRe process in India is crucial for future U.S. deployments. Another critical execution risk is the necessity to validate the CuRe deployment process in India before scaling it to U.S. facilities ^{[1][2][3][4][5][6]}. Insights gained from the India launch will be instrumental in dictating the pace and sequence of future U.S. conversions ^[1][2][3][9]. There is also a potential impact on Section 45X tax credit eligibility during this transition period ^{[1][2][3][4][5][6]}. First Solar management strategically chose India as the initial conversion site to refine the deployment process in an environment where the earnings impact would be minimal ^[1][2][3][8].

First Solar has not provided specific module volume sold guidance for Q1 2027 as of November 3, 2026 ^[1][2][3]. Guidance for 2027 operational metrics is expected in future quarterly updates or the annual earnings release ^[1][2][3]. Key production milestones for 2027 include the start of Series 7 CuRe conversion in India in Q1 2027 ^[1][4][2][3], with expected output of 2.2–2.6 GW ^[1][4][2][3]. South Carolina is projected to yield 2.2–2.5 GW, with phase two launching mid-2027 ^[1][4][2][3]. The Ohio perovskite pilot line is expected to be operationally ready in the first half of 2027 ^[1][4][2][3]. A decision on the long-term status of the 1.8 GW Malaysia facility is anticipated in the first half of 2027 ^[1][3].

Market analysts estimate First Solar's Q1 2027 revenue at approximately $1.28 billion and EPS at $5.05 ^[3][5]. These figures are subject to change based on actual volume realized, the pricing environment, and Section 45X tax credit realizations ^[3][5]. Bullish catalysts include sustained U.S. demand driven by AI and industrial growth, along with the potential benefits of the Section 232 trade proclamation favoring domestic manufacturers ^[1][3]. Bearish risks include project delays from permitting, financing, or local opposition, intense pricing competition, and the binary decision regarding the Malaysia facility's future ^[1][3].